The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, prospective phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to anti-EGFR agents (HGCSG1801): Updated analyses.
 
Hiroshi Nakatsumi
Honoraria - Daiichi Sankyo; Viatris
 
Kazuaki Harada
Speakers' Bureau - AstraZeneca; Bayer; Bristol Myers Squibb; DAIICHI SANKYO COMPANY, LIMITED; Lilly; Merck Serono; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Atsushi Ishiguro
No Relationships to Disclose
 
Kentaro Sawada
No Relationships to Disclose
 
Susumu Sogabe
No Relationships to Disclose
 
Takayuki Ando
No Relationships to Disclose
 
Yusuke Sasaki
No Relationships to Disclose
 
Ayumu Yoshikawa
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Bayer; Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Merck; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
 
Masayoshi Dazai
No Relationships to Disclose
 
Miki Tateyama
No Relationships to Disclose
 
Osamu Muto
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly; Takeda
 
Tamotsu Sagawa
No Relationships to Disclose
 
Tetsuhito Muranaka
No Relationships to Disclose
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Ryo Takagi
No Relationships to Disclose
 
Yuh Sakata
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha